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choice for long-term near-infrared imaging of
immune cells in vivo†
Richard J. Mellanby,‡*ab Jamie I. Scott,‡a Iris Mair,a Antonio Fernandez, a
Louise Saul,b Jochen Arlt, c Monica Moral d and Marc Vendrell *a
Herein tricarbocyanine N-triazoles are ﬁrst described as a rationally-designed near-infrared (NIR) structure
overcoming the brightness and photostability limitations of tricarbocyanines for long-term in vivo imaging.
The straightforward synthetic approach and the wide availability of alkynes makes this strategy a versatile
methodology for the preparation of highly stable N-substituted tricarbocyanines. Furthermore, we validated
CIR38M as a non-transferable marker to monitor the fate of therapeutic T cells non-invasively in vivo,
showing enhanced performance over conventional NIR ﬂuorophores (i.e. DiR, IR800CW and indocyanine
green) as well as compatibility with human cells for translational studies. CIR38M is able to track over time
smaller numbers of T cells than current NIR agents, and to visualise antigen-driven accumulation of
immune cells at speciﬁc sites in vivo. This chemical technology will improve longitudinal imaging studies to
assess the eﬃcacy of cell-based immunotherapies in preclinical models and in human samples.Introduction
In vivo optical imaging has revolutionised our ability to visualise
biological processes with high resolution in intact organisms.
Most in vivo imaging uorophores rely on near-infrared (NIR)
chemical scaﬀolds as they allow deep penetration with minimal
photodamage and low tissue autouorescence.1,2 Many NIR
uorophores have been described for bioimaging applications,
ranging from analyte detection to image-guided surgery.3–10
Choi, Henary and Frangioni among others recently exploited
the diversication of NIR cyanine uorophores for structure-
inherent targeting of diﬀerent tissues.11–13 Zwitterionic hepta-
methine cyanine analogues have also been recently described
as NIR agents with enhanced capabilities for cell, tissue and
in vivo imaging.14–16 Among these structures, the sulfonatedammation Research, The University of
16 4TJ Edinburgh, UK. E-mail: marc.
he Roslin Institute, Division of Veterinary
, Hospital for Small Animals, Easter Bush
mail: richard.mellanby@ed.ac.uk
ersity of Edinburgh, James Clerk Maxwell
Edinburgh, UK
iversity of Castilla-La Mancha, 02071
(ESI) available: Additional details for
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Chemistry 2018heptamethine cyanine dye Indocyanine Green (ICG) is the only
clinically-approved NIR dye for studies in humans.17 The
structurally-related IR800CW uorophores have recently
entered clinical trials as biomarker-labelling molecules for
uorescence-assisted surgery.18 In both ICG and IR800CW, the
potential aggregation of the heptamethine cyanine scaﬀold is
minimised by the incorporation of negatively-charged groups
(i.e. sulfonates); however, these preclude cell uptake and
impede long-term tracking of small populations of cells in vivo.
As an alternative, tricarbocyanine N-amines have been reported
as cell-permeable NIR uorophores, and they can be prepared
via nucleophilic substitution of the IR780 tricarbocyanine core
with amines (1, Fig. 1).19–22 Their straightforward chemistry has
enabled their adaptation to diversity-oriented studies,23–26 but
most tricarbocyanines N-amines show low quantum yields and
rapid photodegradation, which compromise their application
for long-term NIR uorescence imaging. We addressed these
shortcomings by rationally designing tricarbocyanine N-tri-
azoles as a new family of bright, photostable and cell-permeable
NIR uorophores containing neutral triazole groups. We
envisaged that the electron delocalization in the triazole ring
would reduce the electron density of N-substituted groups, thus
minimizing intramolecular quenching and photodegradation
of the tricarbocyanine core. To date, tricarbocyanine N-triazoles
had not been isolated because of the lack of synthetic
approaches that were compatible with the relatively unstable
intermediate tricarbocyanine azide. Herein we describe
a synthetic approach for the isolation of tricarbocyanine N-tri-
azoles in reasonable yields and high purities.Chem. Sci.
Fig. 1 (a) Chemical structures and properties of isosteric tricarbo-
cyanine N-amines (1) and N-triazoles (2) in EtOH. (Inset) Absorbance
pictograms of compounds 1 and 2 (10 mM). (b) Photostability analysis of
compounds 1 (blue) and 2 (green) (both at 50 mM in PBS) under
continuous light irradiation. Solid lines correspond to one phase
exponential decay regressions for both sets of values. (Inset) NIR
ﬂuorescence pictograms of compounds 1 and 2 (10 mM in PBS) before
and after UV light irradiation. (c) Pseudo-coloured electronic distri-
bution maps for compounds 1 (top) and 2 (bottom) in their funda-
mental state.
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View Article OnlineResults and discussion
Design and synthesis of tricarbocyanine N-triazoles
Nucleophilic substitution of IR780 with sodium azide in
DMF : H2O (1 : 1) followed by rapid DCM extraction and 1,3-
Huisgen copper-catalysed cycloaddition rendered tricarbocya-
nine N-triazoles (2, Fig. 1 and 2). Triazole derivatives displayFig. 2 Chemical synthesis of CIR ﬂuorophores. (a) Structures of selected
(red) spectra of CIR38 as a representative CIR ﬂuorophore. (c) Fluoresce
CD4+ T cells (5 105 cells, 10 mM PBS, lexc.: 790 nm; lem.: 820 nm). Value
the mean aggregate size of IR780 and CIR38 in aqueous media (100 mM
are represented as means  s.e.m (n ¼ 3).
Chem. Sci.superior spectral properties when compared to their isosteric
tricarbocyanine N-amines, despite only diﬀering in two
nitrogen atoms being replaced by methylene groups. In addi-
tion to red-shied excitation and emission wavelengths, tri-
carbocyanine N-triazoles exhibit higher extinction coeﬃcients
and quantum yields (i.e. 3% for 1, 10% for 2) with 30-fold
increase in brightness and remarkably enhanced photostability
(Fig. 1). To analyse the diﬀerential behaviour of isosteric amine
(1) and triazole (2) uorophores, we determined their electron
density distributions and transitions with Gaussian 09 (Fig. 1
and S1†).27
These studies highlight the phenyltriazole group as the most
electron-decient region within 2 (Fig. 1c), minimising any
intramolecular quenching. Electronic transitions for both tri-
carbocyanines 1 and 2 involve charge transfer processes from the
heptamethine core to the phenylpyrrolidine in compound 1 (i.e.
a-HOMO to a-LUMO and b-HOMO to b-SOMO) or to the phe-
nyltriazole in compound 2 (i.e. b-HOMO to b-SOMO) (Table S1†).
However, the bridgehead nitrogen atom of the pyrrolidine ring in
compound 1 shows signicantly higher contribution to a-LUMO
(6%) and b-SOMO (6%) than the corresponding nitrogen atom of
the triazole ring in compound 2 (2% to its b-SOMO) (Fig. S1†).
This observation conrms our hypothesis that the reduced elec-
tron density at the bridgehead nitrogen atom in tricarbocyanine
N-triazoles results in enhanced photostability upon photoexcita-
tion. Altogether, the properties of the tricarbocyanine N-triazole
scaﬀold as a bright, cell-permeable and photostable NIR struc-
ture encouraged us to explore its potential to produce new uo-
rophores able to track small populations of cells in vivo for longer
periods of time than currently available NIR dyes.Chemical optimisation of a photostable NIR uorophore for
labelling CD4+ T cells
Cellular immunotherapies represent promising strategies for
treating disorders driven by malfunctioning immune responses,CIR ﬂuorophores (see Table S2†). (b) Absorbance (green) and emission
nce NIR intensity of selected CIR ﬂuorophores upon incubation with
s are represented as means s.e.m (n ¼ 3). (d) Time-course analysis of
PBS) determined by dynamic light scattering at r.t. for up to 8 h. Values
This journal is © The Royal Society of Chemistry 2018
Fig. 3 CIR38M brightly labels CD4+ T cells with no leaking to neigh-
bouring cells. (a) Chemical structure of CIR38M and ﬂuorescence
quantum yield in PBS (relative to ICG). (b) Murine CD4+ T cells were
labelled with CIR38M (10 mM, 2 min) and cultured on anti-CD3 and
anti-CD28 coated plates. NIR ﬂuorescence emission was measured by
ﬂow cytometry on day 0 (solid), day 1 (dashed) and day 3 (dotted),
compared to unlabelled cells (shaded). (c, d) CD4+ T cells expressing
the congenic marker CD45.2 were labelled with CIR38M and co-
cultured with equal numbers of unlabelled CD4+ T cells expressing the
congenic marker CD45.1. After 3 days of in vitro culture, ﬂuorescence
emission of CD45.1+ and CD45.2+ cells were assessed by ﬂow
cytometry.
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View Article Onlineincluding cancer, chronic infections and autoimmune
diseases.28–34 Among these, T cell immunotherapies have
shown great potential, in both experimental models and
human patients.35–39 For instance, in cancer immunotherapy,
tumour-responsive T cells are isolated from the peripheral
blood of patients, expanded ex vivo and then transferred back
to elicit anti-tumour immune responses. One important
obstacle in the clinical translation of T cell immunotherapies
is the lack of chemical agents to track post-transferred ther-
apeutic cells in vivo.40
Longitudinal imaging allows researchers to evaluate
whether T cells reach and accumulate at the site of disease,
particularly shortly aer the transfusion of the cells, when
adverse events may occur. Despite the utility of magnetic
resonance imaging (MRI) and radionuclide-based imaging for
cell tracking,41–43 their respective limited sensitivity and safety
concerns hamper their utility to detect small numbers of
therapeutic T cells (e.g. <10 000 cells) in vivo and at multiple
time points. Using the above mentioned synthetic approach,
we prepared a collection of ‘click’ infrared (CIR) uorophores
by modifying IR780 with 46 structurally-diverse alkynes
(Fig. 2a). CIR uorophores were isolated by semi-preparative
HPLC in very high purities (>95%), and, unlike amino-
derivatised tricarbocyanines,44 all CIR uorophores showed
excitation and emission wavelengths in the NIR window (lexc.
 780–800 nm, lem.  805–840 nm) (Fig. 2b and Tables S2 and
S3†). Given the broad availability of alkyne building blocks
and versatility of the synthetic approach, this route might
become the methodology-of-choice to produce bright and
photostable NIR dyes via functionalisation of tricarbocya-
nines with N-substituted groups.
Next, we evaluated the uorescence emission of the 46 CIR
uorophores upon incubation with murine T cells, and CIR38
showed the brightest uorescence emission (Fig. 2c). Since the
derivatisation of uorescent sulfonamides with 1,2,3-triazole
groups has been recently reported to produce water-soluble
carbonic anhydrase inhibitors with optimal properties for in
vivo studies,45 we envisaged that the neutral uncharged char-
acter of CIR38 would also enhance the solubility of the tri-
carbocyanine core and form less non-uorescent aggregates in
aqueous media. We compared water solutions of CIR38 and the
generic heptamethine structure IR780 by dynamic light scat-
tering, and observed that CIR38 formed less insoluble aggre-
gates in water (Fig. 2d), highlighting the pyridinyl-triazole
moiety as an eﬀective chemical group to enhance the solu-
bility of heptamethine dyes. Furthermore, CIR38 showed
excellent photostability, retaining full chemical integrity even
aer 12 h of continuous UV light irradiation (Fig. S2†). Based on
these results, we synthesized both maleimide (CIR38M) and
succinimidyl ester (CIR38SE) analogues to increase its intra-
cellular retention (Fig. 3a and Scheme S1†). The derivatisation
of CIR38 with reactive groups did not aﬀect the NIR spectral
properties nor the uptake in murine CD4+ T cells (Fig. S3†). We
selected CIR38M as a uorophore with similar spectral prop-
erties to NIR commercially available dyes (Table S4†) and
optimal features for intracellular labelling of CD4+ T cells under
physiological conditions.This journal is © The Royal Society of Chemistry 2018In vitro characterisation of CIR38M for murine T cell imaging
First, we examined the staining of CD4+ T cells following rapid
2 min incubation with diﬀerent concentrations of CIR38M, and
observed that the incubation of CD4+ T cells with 10 mM
CIR38M provided very bright uorescence signals, close to
saturation levels (Fig. S4†). Next, we assessed the intensity of
CIR38M aer several cell divisions by stimulating CD4+ T cells
with plate-bound anti-CD3/CD28 antibodies and measuring the
NIR uorescence emission for several days. As shown in
Fig. S5,† a smaller decline in uorescence emission was
observed aer 3 days of in vitro stimulation in CIR38M-labelled
CD4+ T cells when compared to CFSE, a standard uorescent
marker of cell proliferation. CIR38M therefore demonstrated
the utility to label T cells for multiple rounds of proliferation
without a major loss of uorescence intensity.
We then analysed the stability of CIR38M labelling and eval-
uated whether the probe leaked to neighbouring cells, which
would lead to the misinterpretation of in vivo imaging data. We
employed CIR38M to label CD4+ T cells expressing the CD45.2
cell marker (i.e. CD45.2+ CD4+ T cells), and co-cultured themwith
the same number of unlabelled CD4+ T cells expressing the
CD45.1 cell marker (i.e. CD45.1+ CD4+ T cells) (Fig. 3c). The
expression of two diﬀerent CD45 congenic markers allowed us to
distinguish between CIR38M-labelled and unlabelled cells in the
co-culture. Flow cytometry analysis aer 3 days under stimula-
tory conditions conrmed the intracellular retention of CIR38M,Chem. Sci.
Fig. 4 Fluorescence cell imaging of CIR38M-labelled T cells. (a)
Brightﬁeld, ﬂuorescence and merged microscope images of CD4+ T
cells after labelling with CIR38M and CellTracker Green. (b) Brightﬁeld,
ﬂuorescence and merged microscope images of CD4+ T cells after
labelling with IR800CW-SE and CellTracker Green. Scale bar: 10 mm.
(c) Plot proﬁle analysis of the ﬂuorescence intracellular staining of
CellTracker Green (green) and CIR38M (red) shown images in (a)
(dashed yellow lines). (d) Intracellular staining of CIR38M conﬁrmed by
comparison ofCIR38M-labelled CD4+ T cells (red) toCIR38M-labelled
CD4+ T cells treated with 0.1% trypan blue (orange).
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View Article Onlineas labelled cells expressed the CD45.2marker but not the CD45.1
marker (Fig. 3d). The uorescence characterisation of CIR38M-
labelled CD4+ T cell lysates also showed that CIR38M was
retained inside cells by forming covalent bonds with intracellular
proteins (Fig. S6†), preventing leakage to neighbouring cells. In
addition, we did not observe signicant diﬀerences in the
viability of CD4+ T cells aer CIR38M treatment nor reduction in
proliferation aer culture for 3 days in stimulatory conditions
(Fig. S7a and b†). The non-invasive character of CIR38M was also
corroborated by measuring the production of key pro-
inammatory cytokines (e.g. TNF-a, GM-CSF) of stimulated
labelled CD4+ T cells, which remained unaltered aer treatment
with CIR38M (Fig. S7c and d†).
Fluorescence microscopy of murine CD4+ T cells
Given the features of CIR38M as a NIR uorophore for non-
invasive labelling of CD4+ T cells, we performed in vitro uo-
rescence microscopy experiments to compare its imaging capa-
bilities to other uorophores emitting in the far NIR region (i.e.
800–900 nm). We compared the uorescence staining of CIR38M
to the commercially available IR800CW-SE, a gold standard in
NIR uorescence labelling,46,47 by treating CD4+ T cells with both
uorophores under the same conditions and visualising them
under a uorescence microscope. Counter-staining with the
green uorophore CellTracker Green was used to conrmCD4+ T
cell labelling. As shown in Fig. 4a and b, the lack of charges and
enhanced permeability of CIR38M led to much brighter staining
of CD4+ T cells than IR800CW-SE. Direct comparison of CIR38M
to IR780M, the maleimide analogue of IR780 (Scheme S2†),
showed similar intensity but more photostable NIR signals with
the former, highlighting the importance of the N-triazole group
within the CIR38M structure (Fig. S8†). Notably, the strong
uorescence emission of CIR38M enabled imaging of labelled
CD4+ T cells using both high and low-power excitation sources
(i.e. Ti-sapphire laser and mercury lamps, respectively) (Fig. S9†)
as well as lowmagnication objectives (Fig. S10†), expanding the
scope of applications for CIR uorophores to various optical
imaging modalities. High-magnication images were analysed
by plot proling (Fig. 4c) and conrmed that CIR38M, like
CellTracker Green, localisedmainly in the cytosol of CD4+ T cells
with preferential accumulation in mitochondria compared to
other organelles (e.g. lysosomes) (Fig. S11†). Flow cytometry
analysis also corroborated over 12-fold higher CD4+ T cell
staining of CIR38M when compared to IR800CW-SE (Fig. S12†),
and its intracellular retention was conrmed by lack of uores-
cence quenching in an exclusion assay with the impermeant dye
trypan blue48 (Fig. 4d).
Altogether, these results validate the applicability of CIR38M
as a bright and non-toxic NIR agent to track the recruitment,
expansion and mobility of CD4+ T cells without aﬀecting their
physiology and with enhanced capabilities over commercially
available NIR dyes (e.g. IR800CW-SE).
In vivo long-term tracking of labelled T cells
Next, we examined the properties of CIR38M for tracking CD4+
T cells in vivo using whole-body NIR uorescence imaging. ToChem. Sci.assess the capabilities of CIR38M for detecting small pop-
ulations of therapeutic T cells, CD4+ T cells were labelled with
CIR38M and sequential dilutions were prepared before being
directly imaged using whole-body imaging acquisition settings.
The limit of detection of CIR38M was around 4000 cells, 3-fold
lower than the conventional NIR cell tracerDiR,49,50 highlighting
the utility of CIR38M for monitoring small numbers of T cells
that could not be detected by other methods (Fig. 5). We then
applied CIR38M in a model of T cell activation, whereby an
antigen was injected subcutaneously together with complete
Freund's adjuvant (CFA), to monitor the dynamics of T cell
activation in vivo. The co-administration of autoantigens and
CFA is one of the most used approaches to induce experimental
disease and to examine T cell activation in vivo. Numerous
models have been described using this approach.51–55 With
these experiments, we examined whether: (1) CIR38M could be
used to image the antigen-specic accumulation of T cells in
vivo, and (2) CIR38M could be used to track T cells longitudi-
nally during the whole process of in vivo activation. To address
the rst question, we transferred CIR38M-labelled CD45.1+
CD4+ OT-II T cells, which express a T cell receptor that responds
to ovalbumin peptide (pOVA), into CD45.2+ CD45.1 host mice.
Host mice were administered a subcutaneous injection of CFA
and pOVA antigen on the le hind leg to recruit the labelledThis journal is © The Royal Society of Chemistry 2018
Fig. 5 Determination of the limit of detection in suspensions of
CIR38M-labelled and DiR-labelled (both at 10 mM) CD4+ T cells by NIR
ﬂuorescence imaging. Values shown as means  s.e.m. Images
acquired in PhotonImager™ (lexc.  760 nm; lem.  800–900 nm).
Max: 2  108 photons per s.
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View Article OnlineOT-II T cells into the antigen-containing site, and CFA and PBS
on the right hind leg as a negative control. We acquired whole-
body uorescence images of the mice 48 h post-injection and
observed that CIR38M-labelled CD4+ T cells preferentially
accumulated in the lymph nodes close to where the pOVA
antigen had been injected (Fig. 6a). The CD45.1+ expression on
OT-II cells allowed the transferred cells to be identied ex vivo
by ow cytometry analysis, and we conrmed over 2-fold higher
CIR38M-labelled cells in the lymph nodes draining the side
immunised with CFA and pOVA when compared to the lymph
nodes draining the side immunised with CFA and PBS (Fig. 6b).
Ex vivo analysis of the lymph nodes conrmed that CIR38M
was only present in CD45.1+ donor cells and had not transferredFig. 6 Site-speciﬁc accumulation of CIR38M-labelled cells in a model
of T cell activation. (a) Whole-body ﬂuorescence images (lexc. 
760 nm; lem.  800–900 nm) of C57BL/6 mice (3 per group) 2 days
after the tail vein i.v. injection of CIR38M-labelled (left) or unlabelled
CD45.1+ CD4+ OT-II T cells (right). Right hind legs (green arrows) were
injected with PBS emulsiﬁed in CFA whereas left hind legs (red arrows)
were injected with 10 mg pOVA emulsiﬁed in CFA. (b) Flow cytometric
ex vivo analysis of inguinal lymph nodes (iLNs) from both left and right
hind limbs of mice that had been injected with CIR38M-labelled CD4+
T cells. Percentages indicate the proportion of CD45.1+ donor cells
within the CD4+ T cell compartment.
This journal is © The Royal Society of Chemistry 2018onto host CD45.1 cells, conrming that no leakage of CIR38M
to other subpopulations of T cells occurred in vivo. These results
corroborate that the uorescence emission of CIR38M directly
correlated to the antigen-specic accumulation of CD4+ T cells
in mice.
To address the second question, we examined CIR38M for
long-term imaging of T cell activation in vivo. CIR38M-labelled
CD45.1+ CD4+ OT-II T cells were transferred into C57BL/6 hair-
less mice, followed by immunisation with CFA and pOVA at both
hind limbs. Whole-body uorescence images were acquired at 2,
4 and 7 days aer immunisation. As shown in Fig. 7a–c, CIR38M-
labelled T cells were clearly visible in the draining lymph nodes
for the entirety of the in vivo activation process. Despite the
highly proliferative environment which occurs when T cells
interact with antigen in draining lymph nodes, quantitative
analysis conrmed that 40% of the transferred T cells still
retained CIR38M at day 4 and over 15% at day 7 (Fig. 7d).
CIR38M-stained T cells were detected in the spleen ex vivo, but
were diﬃcult to image in whole bodies due to its deep location in
vivo. The lack of NIR uorescence emission in other immune
cells, most importantly CD11b+ phagocytic myeloid cells,
corroborated the applicability of CIR38M to faithfully identify
the originally labelled T cells (Fig. S13†). Furthermore, we
conrmed the presence of CIR38M-labelled cells by ex vivo
analysis using ow cytometry and NIR tissue imaging (Fig. S14†).
Furthermore, we compared the sensitivity of CIR38M and
DiR for detecting post-transferred cells in mice. We injectedFig. 7 Long-term longitudinal tracking of CIR38M-labelled CD4+ T
cells in vivo. C57BL/6 (B6.Cg-Tyrc-2J Hrhr/J) mice were injected i.v. (tail
vein) with CIR38M-labelled or unlabelled pOVA-reactive CD45.1+
CD4+ OT-II T cells and immunised by injection of pOVA and CFA into
each limb. Whole-body in vivo ﬂuorescence images (lexc.  760 nm;
lem. 800–900 nm) of representativemice (3 per group) injectedwith
CIR38M-labelled or unlabelled T cells were acquired on (a) day 2 (b)
day 4 and (c) day 7, prior to organ harvest and ﬂow cytometry. (d)
Proportion of donor cells retaining NIR ﬂuorescence in the inguinal
lymph nodes (iLN) draining the immunisation site and the spleen on
days 4 and 7. Values as means  s.e.m (n ¼ 3 per group).
Chem. Sci.
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View Article Onlinesmall numbers of CIR38M or DiR-labelled Tg4 CD4+ T cells,
which express a transgenic T cell receptor that responds to
myelin basic protein (MBP), into mice that were immunised
with MBP peptide, and monitored their accumulation in
antigen-treated lymph nodes by whole-body imaging. Brighter
signals were detected for CIR38M-labelled cells (Fig. S15†),
conrming its suitability for NIR imaging of activated CD4+ T
cells even when low numbers of cells are recruited. Finally, to
assess any potential eﬀects of CIR38M-labelled cells on T cell
physiology upon in vivo activation, we compared the recruit-
ment of T cells to the lymph nodes in mice that had either
received labelled or unlabelled CD45.1+ CD4+ OT-II T cells. We
found no signicant diﬀerences between the absolute numbers
nor the proportions of CD45.1+ CD4+ OT-II T cells at any of the
time points, which conrms the non-perturbative character of
CIR38M for non-invasive in vivo imaging of cellular localisation
and proliferation (Fig. S16†). We also examined any potential
systemic toxicity derived from the injection of CIR38M-labelled
CD4+ T cells. We analysed the biochemical prole of serum
from mice that had been immunised with pOVA and CFA and
injected the same amounts of either CIR38M-labelled or non-
labelled CD45.1+ CD4+ OT-II T cells. Serum biochemistry was
performed from mice that had been administered either
CIR38M-labelled or unlabelled cells, and no signicant diﬀer-
ences were observed between the two groups in any of theFig. 8 Ex vivo staining of human T cells with CIR38M. (a) Flow cyto-
metric analysis of human CD4+ T cells from peripheral blood after
labelling with CIR38M and culture with equal amounts of antigen-
presenting cells and 2 mg mL1 soluble anti-CD3. NIR ﬂuorescence on
day 0 (solid), day 1 (dashed) and day 3 (dotted) in comparison to
unlabelled cells (shade). (b) Analysis of human CD4+ T cells labelled
with CIR38M (red) or ICG (green) under the same conditions. (c) Equal
numbers of human CD4+ T cells were incubated with CIR38M or PBS,
incubated overnight at 37 C and viable cells were counted 24 h later.
Values represented as means  s.e.m (n ¼ 3); p > 0.05 for n.s. (d)
Human CD4+ T cells were incubated with CIR38M or PBS and co-
cultured with antigen-presenting cells in the presence of 2 mg mL1
soluble anti-CD3. GM-CSF concentrations in the supernatant were
determined by ELISA 72 h later. Values represented as means  s.e.m
(n ¼ 3); p > 0.05 for n.s.
Chem. Sci.analytes measured (Table S5†). Furthermore, H&E staining of
formalin-xed livers and kidney sections revealed no tissue
pathology aer administration of CIR38M-labelled cells
(Fig. S17†).Ex vivo staining of human CD4+ T cells
With the aim of assessing the translational potential of CIR38M
in adoptive T cell transfer clinical studies, we labelled human
CD4+ T cells from the peripheral blood of healthy volunteers.
We observed that 2 min treatments with 10 mM CIR38M eﬀec-
tively stained human CD4+ T cells, with the cells remaining
clearly labelled aer 3 days of stimulation (Fig. 8a).
We also compared the uorescence staining of human CD4+
T cells with CIR38M to the FDA-approved ICG, and observed
that CIR38M-labelled cells were over an order of magnitude
brighter than ICG-labelled cells under the same conditions
(Fig. 8b). Subsequent culture and analysis of the CIR38M-
labelled cells showed that the probe did not induce signicant
cytotoxicity in resting human CD4+ T cells aer 24 h (Fig. 8c) or
aﬀected the cytokine expression (e.g. GM-CSF) of activated T
cells cultured for 3 days under stimulatory conditions (Fig. 8d).
The high stability and neutral character of CIR38M asserts its
utility for longitudinal imaging studies of murine and human T
cell mobility in both preclinical imaging as well as clinical
research.Conclusions
This is the rst report of tricarbocyanine N-triazoles as a new
family of NIR dyes overcoming the limitations of tricarbocya-
nines for long-term in vivo uorescence cell tracking. We
rationally designed tricarbocyanine N-triazoles as a NIR struc-
ture with brighter uorescence emission and minimal photo-
degradation by theoretical calculations of electron density at the
bridgehead nitrogen atoms of the tricarbocyanine core. We have
also developed a one-pot synthetic methodology compatible
with a broad range of alkyne building blocks, making this
strategy an optimal approach for the preparation of highly
photostable NIR agents. We further optimised the tricarbocya-
nine N-triazole CIR38M as a non-transferable marker of thera-
peutic immune cells, both from mouse and human origin. We
demonstrated that CIR38M can track post-transferred T cells in
vivo at multiple time points as well as detect antigen-driven
accumulation of T cells at specic sites. CIR38M can label
small populations of T cells with high sensitivity (i.e. around
4000 cells) and with cells being detectable in vivo over 7 days
post-transfer. Tricarbocyanine N-triazoles open multiple
opportunities for in situ NIR imaging of therapy eﬃcacy and
disease progression in preclinical and clinical research.Experimental section
General materials
Commercially available reagents were used without further
purication. Thin-layer chromatography was conducted on
Merck silica gel 60 F254 sheets and visualised by UV (254 andThis journal is © The Royal Society of Chemistry 2018
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View Article Online365 nm). Silica gel (particle size 35–70 mm) was used for column
chromatography. 1H and 13C spectra were recorded in a Bruker
Avance 500 spectrometer (at 500 and 125 MHz, respectively).
Data for 1H NMR spectra reported as chemical shi d (ppm),
multiplicity, coupling constant (Hz) and integration. Data for
13C NMR spectra reported as chemical shis relative to the
solvent peak. HPLC-MS analysis was performed on a Waters
Alliance 2695 separation module connected to a Waters
PDA2996 photodiode array detector and a ZQ Micromass mass
spectrometer (ESI-MS) with a Phenomenex® column (C18, 5 mm,
4.6  150 mm). Compounds were puried using a Waters semi-
preparative HPLC system using a Phenomenex® column (C18
Axial, 10 mm, 21.2  150 mm) and UV detection. HRMS (ESI
positive) were obtained in a LTQ-FT Ultra (Thermo Scientic)
mass spectrometer.
Chemical synthesis
Compound 1 was synthesized following previously reported
procedures.44 1H NMR (500 MHz, MeOD) d 7.42–7.21 (m, 12H),
7.05–6.94 (m, 4H), 5.61 (d, J ¼ 12.7 Hz, 2H), 4.64–4.57 (m, 1H),
4.46–4.36 (m, 1H), 4.28–4.18 (m, 1H), 4.18–4.10 (m, 1H), 3.84 (t, J
¼ 7.3 Hz, 4H), 3.64–3.56 (m, 1H), 2.68 (s, 4H), 2.39–2.31 (m, 1H),
1.91–1.75 (m, 6H), 1.60 (d, J ¼ 7.1 Hz, 12H), 1.03 (t, J ¼ 7.4 Hz,
6H). 13C NMR (126 MHz, MeOD) d 128.5, 127.8, 126.9, 126.6,
121.5, 121.4, 121.1, 107.9, 91.9, 73.9, 62.5, 55.3, 46.6, 42.4, 31.4,
28.2, 28.1, 28.0, 19.4, 10.4.
General synthesis of CIR uorophores
To a solution of IR780 (300 mg, 0.44 mmol, 1 eq.) in DMF (2
mL), was added sodium azide (145 mg, 2.2 mmol, 5 eq.) in H2O
(2 mL). The resulting mixture was stirred at 70 C for 20 min.
The reaction was then cooled down, diluted with CH2Cl2 (20
mL) and washed with H2O (1). Combined organic layers
containing the IR780-azide intermediate (conrmed by HPLC-
MS; m/z: 546) were evaporated and used without further puri-
cation. IR780-azide was dissolved in 15 mL CH2Cl2 and ali-
quoted to react with diﬀerent alkynes (typically, in batches of 10
diﬀerent alkynes). To each aliquot, we added CuSO4 (14 mg,
0.08 mmol, 2 eq.), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]
amine (TBTA) (42 mg, 0.08 mmol, 2 eq.) and sodium ascor-
bate (16 mg, 0.08 mmol, 2 eq.) pre-dissolved in DMF : H2O
(1 : 1, 0.2 mL), and the alkynes (0.44 mmol, 10 eq.). The
resulting mixtures were stirred at r.t. typically for 2 h (longer
reaction times depending on the alkynes). The crude reaction
mixtures were diluted in CH2Cl2 (10–20 mL), and the organic
phases were washed with H2O (3  10 mL). The organic extracts
were dried over MgSO4, ltered and evaporated under reduced
pressure. The resulting crudes were then puried by semi-
preparative HPLC to yield CIR uorophores (full character-
isation data in Tables S2 and S3†).
Compound 2. 1H NMR (500 MHz, MeOD) d 8.89 (s, 1H), 8.03
(d, J ¼ 7.0 Hz, 2H), 7.57 (dd, J ¼ 8.3, 6.9 Hz, 2H), 7.49 (t, J ¼
7.5 Hz, 1H), 7.44–7.38 (m, 4H), 7.34 (d, J ¼ 7.8 Hz, 2H), 7.25 (s,
2H), 6.95 (d, J ¼ 14.1 Hz, 2H), 6.38 (d, J ¼ 14.1 Hz, 2H), 4.17 (t, J
¼ 7.4 Hz, 4H), 2.96–2.76 (m, 4H), 2.26–2.08 (m, 2H), 1.89 (q, J ¼
7.4 Hz, 4H), 1.36 (s, 6H), 1.31 (s, 6H), 1.06 (t, J ¼ 7.4 Hz, 6H). 13CThis journal is © The Royal Society of Chemistry 2018NMR (126 MHz, MeOD): d 173.1, 148.1, 147.6, 142.1, 141.6,
141.1, 129.5, 128.9, 128.7, 128.5, 126.4, 125.5, 125.4, 124.8,
122.1, 111.1, 101.4, 49.1, 45.4, 26.6, 26.5, 24.1, 20.6, 20.5, 10.2.
Compound CIR38M. Chemical synthesis detailed in Scheme
S1.† To a solution of CIR38-COOH (10mg, 0.01mmol, 1 eq.) and
(1-cyano-2-ethoxy-2-oxoethylidenaminooxy) dimethylaminomo-
rpholino-carbenium hexauorophosphate (COMU) (10 mg,
0.02 mmol, 2 eq.) dissolved in DMF (0.4 mL) was added DIPEA
(4.1 mL, 0.02 mmol, 2 eq.). The mixture was stirred at r.t. for
15 min. Next, 2-maleimidoethylamine (4.5 mg, 0.02 mmol,
2 eq.) and DIPEA (4.1 mL, 0.02 mmol, 2 eq.) were added in DMF
(0.2 mL). The mixture was stirred at r.t. for 2 h. Then, H2O
(20 mL) was added to the reaction mixture and the organic layer
was extracted with CH2Cl2 (3  20 mL). The organic extracts
were dried over MgSO4, ltered and evaporated under reduced
pressure. The resulting crude was then puried by semi-
preparative HPLC to render CIR38M as a green solid (4 mg,
37% yield).
1H NMR (500 MHz, MeOD) d 8.85 (s, 1H), 8.67 (d, J ¼ 4.9 Hz,
1H), 8.30 (d, J ¼ 7.9 Hz, 1H), 8.06 (t, J ¼ 7.8 Hz, 1H), 7.50 (d, J ¼
4.9 Hz, 1H), 7.42–7.36 (m, 3H), 7.35–7.31 (m, 2H), 7.27–7.21 (m,
2H), 6.92 (dd, J ¼ 14.1, 4.8 Hz, 2H), 6.82 (s, 1H), 6.37 (d, J ¼
14.1 Hz, 2H), 4.22–4.09 (m, 4H), 3.62 (dt, J ¼ 750.8, 5.8, 4.1 Hz,
3H), 3.39–3.34 (m, 3H), 2.88 (s, 4H), 2.66 (d, J¼ 9.4 Hz, 1H), 2.14
(t, J ¼ 7.3 Hz, 3H), 1.92–1.78 (m, 4H), 1.69–1.60 (m, 4H), 1.35 (s,
6H), 1.27 (s, 6H), 1.04 (t, J ¼ 7.4 Hz, 3H). 13C NMR (126 MHz,
MeOD) d 174.7, 173.1, 172.9, 171.1, 149.6, 148.9, 148.0, 147.3,
142.1, 142.0, 141.5, 141.4, 141.2, 141.1, 137.7, 134.1, 128.5,
126.5, 125.4, 125.4, 123.7, 122.1, 120.4, 111.1, 111.1, 101.6,
101.5, 49.1, 49.1, 48.2, 45.4, 43.8, 37.5, 37.1, 35.1, 26.8, 26.6,
26.5, 25.9, 24.8, 24.1, 24.1, 20.6, 20.4, 10.2. HRMS:m/z [M+] calcd
for C52H59N8O3: 843.4705; found: 843.4660.In vitro spectral measurements
Spectroscopic and quantum yield data were recorded on
a Synergy HT spectrophotometer (Biotek). Compounds were
dissolved at the indicated concentrations and spectra were
recorded at r.t. Spectra are represented as means from at least
two independent experiments with n ¼ 3. Relative quantum
yields were calculated by measuring the integrated emission
area of the uorescence spectra and comparing it to the area
measured for the standard56 (e.g. for CIR uorophores, ICG was
used as the reference).Calculations
All quantum chemical calculations were performed with
Gaussian 09 (Revision D.01).27 Ground state geometries of
compounds 1 and 2 were optimised using the density function
theory (DFT) with B3LYP57,58 M06-2X,59 PBE0 (ref. 60) and
wB97xd61 functionals together with the Pople's basis set 6-31G*.
Geometry optimisations were performed both in the gas phase
and in EtOH, where the solvent was described by the Polarizable
Continuum Model (PCM).62 The nature of the excitation ener-
gies, oscillator strengths and contributions of the diﬀerent
orbitals involved in the electronic transitions were calculatedChem. Sci.
Chemical Science Edge Article
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View Article Onlineusing time-dependent density functional theory (TD-DFT) at the
selected levels of theory, both in gas phase and in EtOH.
Particle size analysis
Themean size of aggregates in aqueous media were determined
by dynamic light scattering using a PS90 Particle Size Analyser
(Brookhaven Instrument Corporation). IR780 and CIR38 were
dissolved in PBS (100 mM) and kept at r.t. to measure the size of
aggregates every 2 h for a total of 8 h. Data is represented as
means  s.e.m from two independent experiments with n ¼ 3.
In vitro labelling and characterisation of CD4+ T cells
Single cell suspensions were made from the spleen aer which
red blood cells were lysed using NH4Cl buﬀer. CD4
+ T cells were
puried by magnetic cell sorting as per manufacturer's
instructions (Miltenyi Biotech). CD4+ T cells were re-suspended
in PBS and then labelled with the probes for 2 min at the stated
concentrations at 37 C. Cells were washed twice with cell
culture medium, aer which they were re-suspended in FACS
buﬀer (PBS, 2% FCS, 0.01% sodium azide) or appropriate cell
culture medium. For ow cytometric analysis, cells were then
incubated with antibodies for 20 min at 4 C. The antibodies
used were anti-CD4-e450 or anti-CD4-PE, anti-CD45.1-FITC or
anti-CD45.1-PE, and anti-CD11b-APC (all from eBioscience).
Samples were also stained with a xable viability dye (conju-
gated with eFluor455, eBioscience) prior to surface staining.
Flow cytometry data were collected using an LSR Fortessa (BD
Biosciences) and analysed using FlowJo soware.
In vitro cell viability and proliferation assays
To study the primary activation of CIR38M-labelled CD4+ T
cells, 2  105 CD4+ Tg4. CD45.1+ T cells were added per well to 2
mg mL1 anti-CD3 and 2 mg mL1 anti-CD28 coated, at-
bottomed 96-well plates. Aer 48 h, cell proliferation was
assessed by the addition of [3H]-thymidine at 0.5 mCi per well for
the last 18 h of culture. [3H]-thymidine incorporation was
measured using a scintillation b-counter (Wallac) as mean
counts per minute (c.p.m). The production of cytokines was
assessed in culture supernatants by ELISA using Ready-SET-Go
ELISA kits according tomanufacturer's instructions aer 72 h of
culture. In some experiments, CD45.1+ and CD45.2+ CD4+ T
cells were co-cultured together to assess the extent of probe
transfer between cells. In addition, in some instances, cells were
double-labelled with 5 mM CFSE and 10 mM CIR38M for 2 min
at 37 C.
Fluorescence microscopy of CD4+ T cells
Single cell suspensions were made from spleens of C57BL/6
mice and red blood cells lysed using NH4Cl buﬀer. CD4
+ T
cells were puried by magnetic cell sorting as per manufac-
turer's instructions, re-suspended in PBS and then labelled with
CellTracker Green (10 mM), MitoTracker Red CMXRos (500 nM)
or LysoTracker Red DND-99 (100 nM) at 37 C, prior to addition
of CIR38M or IR800CW-SE (10 mM) and incubation at 37 C.
Cells were washed twice with cell culture medium, twice in PBS,Chem. Sci.before re-suspension of the cell pellet in 1% PFA. T cells were
mounted and imaged under a uorescence microscope (Nikon
Ti Eclipse) using a 60 oil immersion objective (NA 1.4) and
a Hamamatsu Orca Flash 4.0 V2 camera for NIR detection.
Excitation was achieved either by a Ti-sapphire laser (Coherent
Mira 900, 740 nm CW) or a 100 W mercury lamp and a NIR
epiuorescence lter cube (EX 747/33, DM 776LP, EM 776LP).
Whole-body uorescence in vivo imaging and ex vivo analysis
C57BL/6 (CD45.1 CD45.2+) and OT-II (CD45.1+ CD45.2) mice
were bred under specic pathogen-free conditions at the
University of Edinburgh. Hair from C57BL/6 mice was removed
using hair clippers followed by application of a coat of Nair and
subsequent wiping with gauze sponges and water. Hairless
albino C57BL/6 (B6.Cg-Tyrc-2J Hrhr/J) mice were purchased
from The Jackson Laboratory. The housing facility was
compliant with Federation of European Laboratory Animal
Science Associations guidelines on screening mice for infec-
tious diseases. All experiments had local ethical approval from
the University of Edinburgh's Animal Welfare and Ethical
Review Body and were performed in accordance with UK legis-
lation. OT-II transgenic mice express an I-Ab-restricted T cell
receptor, which is reactive toward ovalbumin peptide 323–
339.63 The ovalbumin peptide (pOVA) was obtained from
Cambridge Research Biochemicals. Tissue culture medium
(RPMI 1640 medium) was supplemented with 2 mM L-
glutamine, 100 U mL1 penicillin, 100 mg mL1 streptomycin,
5  105 M 2-ME (all from Invitrogen Life Technologies) and
10% FCS (Labtech).
Albino hairless female C57BL/6 (CD45.2) mice were intrave-
nously injected with 20  106 CD45.1+ CD4+ OT-II T cells which
had been labelled or not with 10 mM CIR38M for 2 min. On the
same day, mice received a 50 mL subcutaneous injection of 10 mg
of pOVA peptide emulsied in 2 mg mL1 CFA, or PBS and CFA
into each hind leg ank. Whole-body in vivo uorescence
images (lexc.  760 nm; lem.  800–900 nm) of representative
mice from both groups (i.e. injected with CIR38M-labelled cells
or injected with unlabelled cells) were acquired on a Photo-
nImager™ (Biospace Lab) on days 2, 4 and 7. Mice were then
culled to harvest the spleens and draining inguinal lymph
nodes for ex vivo tissue imaging and analysis by ow cytometry
as described above.
For CIR38M vs. DiR comparative analysis, 106 CD4+ Tg4 T
cells were transferred into B10.PLxC57BL/6 mice followed by
subcutaneous immunisation with 10 mg of MBP Ac1-9(4Tyr)
peptide emulsied in CFA containing 50 mg of heat-killed
Mycobacterium tuberculosis H37Ra at a total nal volume of
100 mL injected subcutaneously into the hind legs. Whole-body
uorescence images of representative mice from both groups
(i.e. injected with CIR38M-labelled cells or DiR-labelled cells)
were acquired on a PhotonImager™ (Biospace Lab) 48 h post-
injection.
Ex vivo labelling of human CD4+ T cells
Ex vivo experiments with fresh human peripheral blood from
healthy donors were approved by the Accredited MedicalThis journal is © The Royal Society of Chemistry 2018
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View Article OnlineRegional Ethics Committee (AMREC, reference number 15-HV-
013), as previously reported.64Human CD4+ T cells were puried
by magnetic cell sorting as per manufacturer's instructions
(Miltenyi Biotech). CD4+ T cells were re-suspended in PBS and
then labelled with CIR38M or ICG (10 mM) at 37 C. Cells were
washed twice with cell culture medium, aer which they were
re-suspended in FACS buﬀer or appropriate culture medium.
Proliferation studies were undertaken by adding 2 105 CD4+ T
cells per well to equal amounts of antigen-presenting cells and 2
mg mL1 soluble anti-CD3 in at-bottomed 96-well plates. The
production of cytokines was assessed in culture supernatants by
ELISA using Ready-SET-Go ELISA kits according to manufac-
turer's instructions (eBioscience) aer 72 h of culture.
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